Treatment with mTOR(C1) inhibitors such as rapamycin or the dual-kinase inhibitor OSI027 reveal similar findings when comparing the effects in glioblastoma and visceral tumors with higher dosing needed for non-CNS tumors [38,39,40,41,42]. The gene discussed is MTOR; the disease is glioblastoma.